Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.62% | -17.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.79% | -20.21% | |||
| Operating Income | -21.79% | 20.21% | |||
| Income Before Tax | 43.93% | -77.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.52% | -67.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.52% | -67.76% | |||
| EBIT | -21.79% | 20.21% | |||
| EBITDA | -22.45% | 20.06% | |||
| EPS Basic | 40.32% | -66.32% | |||
| Normalized Basic EPS | -26.59% | 21.62% | |||
| EPS Diluted | 40.32% | -66.32% | |||
| Normalized Diluted EPS | -26.59% | 21.62% | |||
| Average Basic Shares Outstanding | -0.32% | 0.88% | |||
| Average Diluted Shares Outstanding | -0.32% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||